Rare disease drug developer BioMarin Pharmaceutical (Nasdaq: BMRN) has submitted an application in the USA for approval to market its pegvaliase, a candidate treatment for phenylketonuria (PKU), a genetic disorder.
Pegvaliase is designed to reduce blood phenylalanine (Phe) levels in adult patients with PKU who have uncontrolled levels on existing management.
"We believe that pegvaliase offers the promise of an important new treatment option for those adult patients with PKU unable to manage their condition with existing treatments,” said global R&D head Hank Fuchs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze